Arcus Biosciences vs Xencor
Arcus Biosciences is the larger business, with $247m of revenue in fiscal 2025 against $126m for Xencor (2.0 times as much). Xencor grew faster (13.7% against -4.3%). Xencor kept more of each dollar of sales as profit: a net margin of -73.2% against -142.9%.
| Latest fiscal year | Arcus BiosciencesRCUS, 2025 | XencorXNCR, 2025 |
|---|---|---|
| Revenue | $247m | $126m |
| Revenue growth | -4.3% | 13.7% |
| Net income | −$353m | −$91.9m |
| Operating margin | -156.3% | — |
| Net margin | -142.9% | -73.2% |
| Return on equity | -63.3% | -14.0% |
| Free cash flow | −$484m | −$138m |
| Cash | $222m | $54.1m |
| Total debt | $100m | $120m |
| Debt to equity | 15.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 601 | 260 |
| Market value | $2.39bn | $2.29bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 18 sales |